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Recently, activating mutations of the hypoxia-inducible factor 2α gene (HIF2A/EPAS1) have been recognized to
predispose to multiple paragangliomas (PGLs) and duodenal somatostatinomas associated with polycythemia,
and ocular abnormalities. Previously, mutations in the SDHA/B/C/D, SDHAF2, VHL, FH, PHD1, and PHD2 genes
have been associated with HIF activation and the development of pseudohypoxic (cluster-1) PGLs. These tumors
overlap in termsof tumor location, syndromic presentation, and noradrenergic phenotype to a certain extent. However,
they also differ especially by clinical outcome and by presence of other tumors or abnormalities. In the present study,1Support: This study was funded by the Eunice Kennedy Shriver National Institute of Child
Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
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568 Hypoxia-Inducible Factor 2α Paragangliomas Fliedner et al. Neoplasia Vol. 18, No. 9, 2016we aimed to establish additional molecular differences between HIF2A and non-HIF2A pseudohypoxic PGLs. RNA
expression patterns ofHIF2A PGLs (n = 6) from 2 patients were compared with normal adrenal medullas (n = 8) and
other hereditary pseudohypoxic PGLs (VHL: n = 13, SDHB: n = 15, and SDHD: n = 14). Unsupervised hierarchical
clustering showed thatHIF2APGLsmade up a separate cluster fromother pseudohypoxic PGLs. Significance analysis
of microarray yielded 875 differentially expressed genes between HIF2A and other pseudohypoxic PGLs after
normalization to adrenal medulla (false discovery rate 0.01). Prediction analysis of microarray allowed correct
classification of allHIF2A samples based on as little as three genes (TRHDE, LRRC63, IGSF10; error rate: 0.02). Genes
with the highest expression difference between normal medulla and HIF2A PGLs were selected for confirmatory
quantitative reverse transcriptase polymerase chain reaction. In conclusion, HIF2A PGLs show a characteristic
expression signature that separates them fromnon-HIF2A pseudohypoxic PGLs. Unexpectedly, themost significantly
differentially expressed genes have not been previously described as HIF target genes.
Neoplasia (2016) 18, 567–576Introduction
Within the last 5 years, the number of gene mutations associated with
paragangliomas (PGLs) and pheochromocytomas (i.e., adrenal PGLs)
has more than doubled [1]. Strong genotype-phenotype associations
including syndromic presentation; tumor location; malignant potential;
and biochemical, metabolomic, and specific imaging phenotypes have
been recognized, indicating the need for identification of individualized
treatment approaches to hereditary PGLs [2–4].
At the gene expression level, two main groups of PGLs have been
identified: those showing increased expression of hypoxia-related genes
(pseudohypoxic PGLs, also referred to as cluster-1) and kinase signaling
genes (cluster-2) [5–7]. Cluster identity of paragangliomas can be well
determined based on metanephrine production because almost
exclusively cluster-2 paragangliomas produce metanephrine. Regardless
of cluster classification, a current concept suggests that inappropriately
elevated HIF signaling may be involved in tumorigenesis of most
mutation-derived PGLs [8]. Qin et al. showed that joint HIF-1α and
HIF-2α stabilization is predominant in all pseudohypoxic PGLs [9].
A recent addition to the list of gene mutations predisposing to
pseudohypoxic PGLs are gain-of-function mutations of hypoxia-
inducible factor 2 alpha (HIF2A or EPAS1) [10]. HIF2A PGLs are
most often multifocal and recurrent, produce norepinephrine, and
occur more frequently in females than males (summarized in [11]). At
least half of the afflicted patients reported to date show syndromic
presentation including polycythemia from early childhood, PGLs at
young age, duodenal somatostatinomas [10,12], and ocular abnormal-
ities [13]. Recently, somaticHIF2A mutations have also been detected
in central nervous system hemangioblastomas [14] and duodenal
gangliocytic PGLs [15], a rare type of tumor composed of neurons,
Schwann cells, and enteric-type neuroendocrine cells that differs from
true PGLs by expression of keratins, pancreatic polypeptide, and other
intestinal regulatory peptides. In the majority of cases, themutations were
found to be somatic and postzygotic; however, rarely, germlinemutations
as well as germline mosaicism have also been reported [16,17].
PGLs have not been previously associated with a comparable
syndromic presentation except for cases of vonHippel–Lindau syndrome,
in which almost always adrenal PGLs rarely co-occur with polycythemia
and/or somatostatinomas [18,19]. Somatostatinomas have previously
been associated with other neuroendocrine syndromes caused by
mutations which predispose to cluster-2 PGLs, i.e., multiple endocrineneoplasia 2B (i.e., RET mutations) [20] and neurofibromatosis 1 (NF1
mutations) [21,22]. Nevertheless, in previous studies, the mRNA
expression profiles of nine cases of HIF2A-mutated PGLs from patients
with and without syndromic presentation clustered with other
pseudohypoxic PGLs [23–26], whereas, surprisingly, three cases showed
more common expression patterns with cluster-2 PGLs [24]. The authors
mentioned that several of the reportedHIF2A tumors were suspected to
carry somatic NF1 mutations; thus, possibly, these three samples were
afflicted with both mutations. HIF2A expression was increased even in
the latter cases compared with cluster-2 PGLs.
Based on distinct clinical presentations of patients with HIF2A
syndrome from patients with other HIF-stabilizing mutations, differences
in the tumor biology and clinical outcome are evident.Despite the fact that
stabilization of HIF-1α and/or HIF-2α occurs due to mutations in any
cluster-1 tumor susceptibility genes, clinical manifestations and outcomes
vastly differ. Particularly for patients with HIF2A mutations, who often
present early with polycythemia and have a high risk to develop metastatic
somatostatinomas and less frequently metastatic PGL and ocular
abnormalities, the development of new, targeted approaches to therapy
is of the essence. To further elaborate if and how HIF2A-related PGLs
differ from non-HIF2A pseudohypoxic PGLs (e.g., SDHx and VHL) on
the molecular level and to identify potentially druggable targets, we
performed a differential gene expression analysis of cluster-1 PGLs.
Results
Identification of a Differentiating Expression Signature in
HIF2A PGLs
Principal component analysis showed that HIF2A tumor samples
have distinct expression characteristics from non-HIF2A pseudohy-
poxic PGLs (Figure 1A). In agreement with that, unsupervised
hierarchical clustering showed that HIF2A PGLs make up a separate
subcluster (cluster-1Ab) within the previously described cluster-1A
(i.e., a joint cluster of SDHB and SDHD-abdominal/thoracic [AT]
PGLs, which is clearly distinguishable from cluster-1B, containing
VHL and SDHD head and neck PGLs [HNPs] in two distinct
subclusters [27]) (Figure 1B). Significance analysis of microarray with
two-class option at a false discovery rate ≤ 0.01 revealed 875
differentially expressed genes in HIF2A PGLs compared with
non-HIF2A pseudohypoxic PGLs after normalization to normal
CA B
Figure 1.Distinct expression pattern ofHIF2A PGLs. (A) Principal component analysis showed thatHIF2A PGLs are clearly distinguishable
from other pseudohypoxic PGLs based on their expression pattern. (B) Hierarchical clustering of all pseudohypoxic PGLs based on
differentially expressed genes observed by significance analysis of microarray showed separate subclustering of HIF2A PGLs in the
previously described cluster-1A (a mixed cluster of SDHB and SDHD-AT PGLs). (C) Top three genes, which allow correct classification of
HIF2A PGLs with an excellent error rate of merely 2%. The y-axis indicates relative gene expression to normal adrenal medulla. Median,
first, and third quartiles of relative expression z-scores of the gene in question are indicated by midline, bottom, and top of the boxes.
Whiskers indicate lowest and highest expression values within 1.5 interquartile ranges of the lower and upper quartile, respectively.
Extreme values are depicted as dots and may be considered outliers.
Table 1. Confusion matrix for classification of HIF-2α samples
HIF2A Other Pseudohypoxic Error Rate
HIF2A 6 0 0.00
Other pseudohypoxic 1 41 0.02
Overall error rate= 0.02
Neoplasia Vol. 18, No. 9, 2016 Hypoxia-Inducible Factor 2α Paragangliomas Fliedner et al. 569adrenal medulla (Figure 1B). Of these 875 genes, 96 were 1.5-fold
more highly expressed in HIF2A than non-HIF2A pseudohypoxic
PGLs, whereas 27 were 1.5-fold more highly expressed in the latter
(Table S1).
Prediction analysis of microarray at a threshold of 2.3 allowed correct
classification of all HIF2A samples based on 354 genes with only one
misclassification of an SDHD adrenal PGL (D31.1) with an error rate
of 0.02 (Table 1). Correct classification among cluster-1 PGLs with this
low error rate was even achieved based on the expression of just three
genes: TRHDE, LRRC63, and IGSF10 (Figure 1C).
HIF-α Target Gene Signature
Comparison of previously reported HIF-1α and HIF-2α target
gene lists with the 875 genes, which were identified to be
differentially expressed between HIF2A and other pseudohypoxic
PGLs by significance analysis of microarray, led to few or no matches
(0%-8.3%; 0/72 [28], 20/443 [29], 2/24 [30], 7/117 [31–33], 21/500
[34]). There was no preference for either HIF-1α or HIF-2α target
genes. When a fold change (FC) threshold equal or greater than 1.5 or
equal or less than −1.5 was chosen, only two reported HIF-1α target
genes (MIF: FC = 1.6, FLT1: FC = −1.7), two HIF-1α and HIF-2α
target genes (KRT19: FC = 1.8, PDK1: FC = −1.56), and one HIF-2αtarget gene remained (PRKCA: FC = −1.59). Surprisingly, the
expression of the HIF-2α target gene PRKCA was significantly
decreased in HIF2A PGLs compared with all other groups.
Moreover, MIF and FLT1 expression changes were in opposing
directions, with MIF being more highly expressed in HIF2A than all
other groups except for SDHD-AT and FLT1 being expressed at
similar levels in HIF2A and normal medulla while being elevated in
all other groups (Figure 2A). Similarly, KRT19 and PDK1 were
changed in opposing directions. KRT19 was downregulated in all
pseudohypoxic PGLs compared with normal medulla and HIF2A
samples, whereas PDK1 was downregulated in HIF2A compared
with normal medulla, SDHB and VHL PGLs.
Overall, these findings may indicate that the hypoxic expression
signatures of HIF2A and other pseudohypoxic PGLs are mainly in
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Figure 2. HIF target gene expression in pseudohypoxic PGLs. (A) Five HIF target genes, which were identified to be differentially
expressed between HIF2A and other pseudohypoxic PGLs. The y-axis indicates normalized gene expression level. Median, first, and third
quartiles of normalized expression z-scores of the gene in question are indicated by midline, bottom, and top of the boxes. Whiskers
indicate lowest and highest expression values within 1.5 interquartile ranges of the lower and upper quartile, respectively. Extreme values
are depicted as dots and may be considered outliers. Overall ANOVA was performed. Asterisks indicate significantly different expression
from HIF2A as determined by post hoc analysis using Dunnett's test (***P ≤ .001, **P ≤ .01, *P ≤ .05). (B and C) Upon restriction of the
1721 differentially expressed genes between normal medulla and pseudohypoxic PGLs to those that have been previously reported as
HIF target genes, separate clustering of HIF2A PGLs was maintained, indicating differences in HIF target gene activation between the
HIF2A PGLs and other pseudohypoxic PGLs. HIF target genes presented in B are from the transcription factor encyclopedia, and those
shown in C are from [29].
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HIF signaling is a common denominator [5,7,35].
To evaluate the overlap in expression between HIF2A and
non-HIF2A pseudohypoxic PGLs, we compared the expression
patterns of all pseudohypoxic PGLs combined (including HIF2A
PGLs) with normal adrenal medulla. Significance analysis of
microarray revealed 1721 differentially expressed genes at a q-value
of 1%. Ingenuity Pathway Analysis (IPA) of the differentially
expressed genes between all pseudohypoxic PGLs and normal
medulla with an FC greater than 1.5 predicted transcription factor
activation, among others, for HIF-1α, HIF-2α, and ARNT2, an
HIFβ subunit (activation z-scores: 2.409, 2.379, and 2.236 and
overlap factors: 1.63*10−5, 1.37*10−5, and 2.236*10−3, respectively).
Genes and changes in expression which led to the prediction of
activation are shown in Table S3. These data suggest that a commonactivation of both HIF-1α and HIF-2α is likely to be present in all
pseudohypoxic PGLs.
Matching the significance analysis of microarray list of differen-
tially expressed genes between normal medulla and all pseudohypoxic
PGLs revealed more matches to reported and predicted HIF target
gene lists (7.9%-20.1%; 9/72 [28], 35/443 [29], 5/24 [30], 14/117
[31–33], 50/500 [34]). Interestingly, despite similar expression
changes in these HIF targets among all pseudohypoxic PGLs
compared with normal medulla, hierarchical clustering of all groups
with either of those HIF target gene lists led to separate clustering of
HIF2A PGLs from non-HIF2A PGLs in a similar manner as when
using all 875 genes (Figure 2, B and C), indicating that HIF2A PGLs
are more similar to each other than non-HIF2A PGLs overall but also
with respect to HIF target genes. Thus, although all pseudohypoxic
PGLs show some agreement in their HIF signature, even when
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Figure 3. Indication of activated pathways in HIF2A PGLs. (A) IPA revealed increased expression of a vast number of genes essential in
oxidative phosphorylation in HIF2A PGLs (red indicates upregulation in HIF2A PGLs compared with pseudohypoxic PGLs). (B) Heatmap
depicting upregulation of oxidative phosphorylation genes in HIF2A PGLs after comparison of differentially expressed genes in HIF2A
compared with other pseudohypoxic PGLs with the oxydative phosphorylation genes listed in the Kyoto Encyclopedia of Genes and
Genomes (red indicates upregulation). (C) Upregulation of several genes for ribosomal proteins led to prediction of increased protein
synthesis and MYCN activation in HIF2A PGLs by IPA.
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This indicates characteristically different nuances of HIF target gene
activation in HIF2A PGLs.
To focus on unique features of HIF2A PGLs on the pathway level,
core analysis was performed using IPA. Oxidative phosphorylation
was reported as top canonical pathway, with 27 of 93 related genes
being more highly expressed in the HIF2A group than the group of
non-HIF2A pseudohypoxic PGLs (Figure 3A). This was confirmed
by matching the significance analysis of microarray list to the genes
listed for oxidative phosphorylation in the Kyoto Encyclopedia of
Genes. Upregulation was evident for 35 of 128 listed genes (Figure
3B). However, as is visible in Figure 3B, very strong upregulation of
oxydative phosphorylation genes was predominant in only four of
six HIF2A samples, which skewed the group median z-score. These
four samples were all from patient H48. The two other HIF2A
samples from patient H49 subclustered with five SDHB PGLs.
Because oxidative phosphorylation was still the top-rated pathway
based on group medians of relative expression and we previously
showed that SDHB and SDHD-AT PGLs have stronger expressionof oxidative phosphorylation genes than VHL and SDHD- HNP,
we still consider this finding interesting because it reflects that
HIF2A PGLs may depend less on glycolytic energy metabolism.
Another pathway reported to be highly activated was EIF2
signaling, with 32 genes from the pathway being upregulated,
including 30 ribosomal proteins. In agreement with that, EIF4E
was predicted to be activated based on upregulation of nine genes
(Table S3, activation z-score = 2.530, overlap P value = .046).
Furthermore, translation, expression, and synthesis of proteins
were suggested to be elevated in HIF2A PGLs based on IPA
downstream analysis. Interestingly, MYCN was predicted to be
activated (activation z-score = 3.599, overlap P value = 1.54*10−5),
which may explain elevated expression of several genes involved in
protein synthesis (Figure 3C).
Unique Features of HIF2A PGLs
To further specify the characteristic expression signature of HIF2A
PGLs, we chose a two-step approach using significance analysis of
microarray, first identifying the differentially expressed genes between
Figure 4. Relative mRNA expression of genes of interest in HIF2A compared with other pseudohypoxic PGLs as assessed by validatory
qRT-PCR. Expression of the candidate markers for HIF2A PGLs, TMEM100, NPY, and LRRC63, was assessed relative to RPLP0 in a vastly
separate sample set than the one assessed for the microarray. Bars indicate group means ± SEM. Overall ANOVA was performed.
Asterisks indicate significantly different expression from HIF2A as determined by post hoc analysis using Dunnett's test (***P ≤ .001,
**P ≤ .01, *P ≤ .05).
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then matching it to a list of genes differentially expressed between
non-HIF2A andHIF2A PGLs (254 genes, q-value 1%). A heatmap of this
characteristic HIF2A-PGL expression signature relative to other pseudo-
hypoxic PGLs is given in Figure S2 and the genes are listed in Table S3.
Genes of Interest
Ten genes of interest were chosen for further exploration by rating
the 875 genes we found to be differentially expressed between HIF2A
and other pseudohypoxic PGLs based on themagnitude of difference in
expression between normal adrenal medulla and HIF2A PGLs and a
false discovery rate below 0.01 in significance analysis of microarray.
Quantitative reverse transcriptase polymerase chain reaction
(qRT-PCR) for a largely separate set of PGL samples was performed
for 9 of the 10 genes of interest and essentially confirmed themicroarray
data for 6 genes (P ≤ .001: TMEM100, NPY, and LRRC63; P ≤ .05:
PTN, GNG11, IL20RA). The three genes most likely to qualify to
distinguish HIF2A PGLs from other pseudohypoxic PGLs were thus
TMEM100, NPY, and LRRC63 (Figure 4), and they potentially play
distinguishing roles in HIF2A PGL tumor biology.
Previously, pseudohypoxic PGLs have been reported to be
highly vascular and exhibit increased VEGF signaling [36]. Toledo
et al. reported similar expression of VEGFA in two cases of HIF2A
PGLs and cluster-1 PGLs, which was significantly higher than in
cluster-2 PGLs [26]. Within our cohort, VEGFA expression was
increased compared with normal medulla in all pseudohypoxic
PGL groups but to a lesser extent in HIF2A than the other groups.
Expression of the VEGF receptors, NRP1 (VEGF165R), KDR
(VEGFR-2), and FLT1 (VEGFR-1), was at similarly low or lower
levels in HIF2A PGLs compared with normal medulla. Gene
expression was significantly elevated in SDHD-HN and VHL PGLs
(KDR); SDHB, VHL, and SDHD-HN PGLs (NRP1); or SDHB,
SDHD-AT, SDHD-HN, and VHL PGLs (FLT1) compared with
HIF2A samples (Figure S1).Discussion
Our gene expression data based on 48 pseudohypoxic PGLs and 8
normal adrenal medullas indicate that HIF2A PGLs show
expression features that on the one hand unite and on the other
hand clearly distinguish them from non-HIF2A pseudohypoxic
PGLs.In support of significant differences in gene expression profiles of
HIF2A and non-HIF2A pseudohypoxic PGLs, correct classification
of HIF2A PGLs was excellent.
Characteristic expression of TRHDE, LRRC63, and IGSF10 was
sufficient to correctly classify all HIF2A PGL samples. In our cohort,
LRRC63 was more highly expressed in HIF2A PGL samples than all
other tissues, including normal medulla. Thus, LRRC63 may play an
essential role inHIF2A PGL development. Currently, the function of
LRRC63 is unknown.
Our data further show decreased expression of IGSF10 and
TRHDE in all non-HIF2A pseudohypoxic tumors relative to normal
medulla and HIF2A PGLs. Interestingly, TRHDE has been shown to
be hypermethylated in oral squamous cell cancers and dysplastic tissue
compared with adjacent normal tissue [37], which generally leads to
decreased transcription. In addition, IGSF10 has been described to be
downregulated in radiation-induced rat osteosarcomas relative to
normal osteoblasts [38]. Thus, decreased TRHDE and IGSF10
expression, possibly caused by hypermethylation, may contribute to
tumorigenesis in non-HIF2A pseudohypoxic PGLs.
Nevertheless, HIF2A-initiated transcription does not seem to play
a major role in the observed differential expression patterns. Our data
showed minimal overlap of differentially expressed genes between
HIF2A and non-HIF2A pseudohypoxic PGLs with previously
published HIF target gene lists. Comparison of the combined
expression patterns of all pseudohypoxic PGLs (including HIF2A)
relative to normal adrenal medulla indicated differential expression of
almost always twice as many HIF target genes upon comparison with
published and predicted HIF target gene lists [28–34]. This confirms
previous reports suggesting a common HIF pathway-related
expression signature for all pseudohypoxic PGLs [5,7,35].
Selected HIF2A target genes, however, did show differences in
expression level between the analyzed pseudohypoxic PGLs,
indicating that slight differences in HIF target gene expression exist
and may contribute to the variation in manifestation between the
analyzed tumor groups. The HIF1A and HIF2A target gene KRT19
is a key player in epithelial to mesenchymal transition and has been
reported to be expressed in neuroendocrine tumors [39]. In addition,
it is used as a marker to detect circulating breast cancer cells and
correlates with highly proliferating tumors and the risk for metastases
[40]. On the contrary, epigenetic downregulation of KRT19 in
SDHB-PGLs has been shown [41,42], and its downregulation
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HIF2A PGLs showed similar KRT19 expression compared with
normal medulla and decreased expression in the other pseudohypoxic
PGLs. In agreement with that, Toledo et al. showed increased mRNA
expression of KRT19 in a HIF2A PGL compared with cluster-1 and
cluster-2 PGLs [26]. KRT19mRNA expression at similar level as seen
in the normal medulla may reflect reduced aggressiveness with slower
tumor progression observed in our HIF2A patient cohort compared
with, e.g., SDHB patients.
Exploration of concerted changes in gene expression in HI-
F2A-related PGLs revealed oxidative phosphorylation and protein
translation/synthesis to be upregulated compared with non-HIF2A
pseudohypoxic PGLs. We previously showed increased expression
of several oxidative phosphorylation genes, but in a less concerted
manner, in SDHB and SDHD-AT PGLs compared with VHL and
SDHD-HN PGLs [27,43]. HIF2A PGLs from patient H48
showed even higher levels of oxidative phosphorylation gene
expression, whereas those of H49 fell into a subcluster shared with
five SDHB PGLs, which we previously showed to have a tendency
for higher expression of oxidative phosphorylation genes, and
surprisingly one SDHD-HN PGL. Thus, expression of oxydative
phosphorylation genes may be very strong in certain HIF2A PGLs
while being comparable to other pseudohypoxic PGLs in others.
Dysfunction of VHL has been reported to cause decreased
oxidative phosphorylation complex subunit expression [44] by way
of HIF signaling and reactive oxygen species generation [45].
Dysfunction of the SDH complex has been previously associated
with reactive oxygen species generation [46–48] and may thus share
a similar mechanism of oxidative phosphorylation gene downregu-
lation for certain mutations. Hervouet et al. [44] used cells which
do not express HIF-1α and showed that presence of HIF-2α
is essential in downregulation of oxidative phosphorylation genes.
In contrast, using the same cell model, Biswas et al. showed
that HIF-1α overexpression (with a background of endogeneous
HIF-2α) led to a decreased level of mitochondrial activity, whereas
HIF-2α overexpression (in absence of HIF-1α) induced mitochon-
drial activity [49]. In agreement with that, Chiavarina et al. showed
that HIF-2α activity increased oxidative phosphorylation gene
expression, whereas it was decreased by HIF-1α activity [50]. In
HIF2A PGLs, activation of HIF-1α is absent or minimal [12,51],
and thus, a similar picture as seen in the model systems of Biswas and
Chiacarina may be present in those tumors, whereas in the other
pseudohypoxic tumors, likely a simultaneous activation of HIF-2α
and HIF-1α is present [9].
Determination of oxidative phosphorylation function in HIF2A
compared with non-HIF2A PGLs or in appropriate PGL cell models
is needed to confirm differential regulation of oxidative phosphor-
ylation by HIF-1α and HIF-2α stabilization. Increased expression of
oxidative phosphorylation genes in some HIF2A PGLs may indicate
that these tumors are not as dependent on theWarburg effect as other
pseudohypoxic PGLs. In agreement with that, our own unpublished
observations indicate that imaging of elevated glucose turnover via
18-fluoro-deoxyglucose is much less specific for HIF2A PGLs than
for other pseudohypoxic PGLs, especially those with SDHB
mutations.
Protein translation has previously been reported to be inhibited by
hypoxia [52], abnormal pVHL [53], and PHD2 [54]. Thus,
decreased protein translation in pseudohypoxic PGLs with PHD2
or VHL dysfunction as well as inhibited PHDs due to SDHxmutations would be expected. Our results show higher expression of
43 ribosomal proteins in HIF2A PGLs compared with the other
pseudohypoxic PGLs, indicating that, as discussed above, exclusive
HIF-2α stabilization may have effects that differ from general hypoxia
or stabilization of all HIF-α subunits.
We identified potential HIF2A PGL markers with distinct
expression in HIF2A PGLs compared with the other pseudohypoxic
PGLs. Of those, TMEM100, LRRC63, and NPY best qualified as
characteristically expressed in HIF2A PGLs. TMEM100 is essential
for epithelial to mesenchymal transition [55], which is required for
maturation and migration of neural crest precursors. In hepatocellular
carcinomas, a tumor suppressor role of TMEM100 by inhibition of
proliferation and metastatic spread has been described [56]. In
agreement, lack of TMEM100 induces VEGFA expression in
myocardial cells [55]. In the HIF2A PGLs, we noticed higher
TMEM100 levels and lower VEGFA expression compared with other
pseudohypoxic PGLs, in which the opposite pattern was observed.
Moreover, the VEGF receptors NRP1, KDR, and FLT1 were
expressed at lower levels in adrenal medulla and HIF2A PGLs
compared with most non-HIF2A PGLs. Thus, HIF2A PGLs may be
less susceptible to antiangiogenic treatment than other pseudohypoxic
PGLs.
NPY has been previously shown to be more highly expressed in
adrenergic than noradrenergic or RET- than VHL-mutated pheo-
chromocytomas [57]. Here we observed NPY expression that was
increased in HIF2A PGLs compared with all other pseudohypoxic
PGLs. Toledo et al. showed decreased expression of NPY in an
HIF2A PGL compared with NF1 and possibly VHL PGLs, whereas
expression level appears similarly low in SDHB as in the HIF2A
sample [26].
In conclusion, HIF2A PGLs share certain features of pseudohy-
poxic PGLs; however, they are also truly distinct. This may be
related to a somewhat different activation pattern of HIF target
gene s , ox ida t i v e phosphory l a t i on gene s , a s we l l a s
angiogenesis-related genes. In addition to the indication that
HIF2A PGLs are less vascular and less affected by oxidative
phosphorylation dysfunction than other pseudohypoxic PGLs,
they also show elevated expression of NPY, protein transcription,
andMYCN activation genes, as has been shown for cluster-2 PGLs.
Thus, unique or even cluster-2–like expression aspects of HIF2A
PGLs will have to be factored in when developing new treatment
strategies for HIF2A PGLs.Material and Methods
All tumor and normal tissue samples were collected and processed
with informed patient consent as previously reported [27]. Normal
adrenal medulla was microdissected from cortex under microscopic
guidance as previously described [58]. In addition to the previously
reported samples, material of six HIF2A tumors from two different
female patients (H48 and H49) were used. Patient H48 underwent
surgery at the age of 29 and had 4 paragangliomas and 2
somatostatinomas removed. The patient later developed asynchro-
nous bilateral pheochromocytomas and additional paragangliomas
as well as somatostatinomas with corresponding metastases. Patient
H49 had a pheochromocytoma and a paraganglioma removed at
the age of 18. Within the same year, somatostatinomas of the
pancreas and duodenum were resected. Patient information is given
in Table 2.
Table 2. Tissue sample information
Mutation Sex Age at Surgery Tissue Type Status
N01 dna m 61 normal dna
N02 dna nk nk normal dna
N03 dna f 53 normal dna
N04–1 dna f 72 normal dna
N0–2 dna f 72 normal dna
N05 dna m 65 normal dna
N06 dna m 56 normal dna
N07 dna m 62 normal dna
B08 SDHB f 30 PHEO Pr-NM
B10 SDHB m 24 PGL Pr-M
B12 SDHB f 9 PGL Mlt-NM
B14 SDHB m 27 PGL Met
B15 SDHB m 38 PGL Pr-M
B16 SDHB f 47 PGL Mlt-NM
B17–1 SDHB f 36 PGL Met
B17–2 SDHB f 36 PGL Met
B18 SDHB m 52 PGL Met
B19 SDHB m 12 PGL Pr-NM
B20 SDHB m 31 PGL Pr-NM
B21 SDHB m 55 PGL Mlt-NM
B22 SDHB m 35 PGL Mlt-NM
B23 SDHB f 35 PGL Met
B24 SDHB m 17 PHEO Mlt-NM
D25 SDHD m 24 HNP Pr-NM
D26 SDHD f 34 HNP Bi-M
D27 SDHD f 49 HNP Pr-NM
D28 SDHD f 61 HNP Pr-NM
D29 SDHD m 16 PHEO Pr-NM
D30 SDHD f 31 PHEO Pr-NM
D31–1 SDHD f 27 PHEO Mlt-NM
D31–2 SDHD f 27 HNP Mlt-NM
D31–3 SDHD f 27 HNP Mlt-NM
D32 SDHD m 48 HNP Bi-NM
D33 SDHD m 61 PHEO Pr-NM
D44 SDHD f 29 HNP Mlt-NM
D35–1 SDHD m 32 PHEO Mlt-NM
D35–2 SDHD m 33 PGL Mlt-NM
V36 VHL f 25 PHEO Bi-NM
V37–1 VHL m 23 PHEO Bi/Mlt-NM
V37–2 VHL m 23 PHEO Bi/Mlt-NM
V38 VHL M 16 PHEO Bi/Rec-NM
V39 VHL m 29 PHEO Pr-NM
V40 VHL m 13 PHEO Bi-NM
V41 VHL f 43 PHEO Pr-NM
V42 VHL m 29 PHEO Bi/Mlt-NM
V43 VHL f 43 PHEO Bi-NM
V44 VHL m 39 PHEO Pr-NM
V45 VHL m 31 PHEO Bi-NM
V46 VHL m 33 PHEO Bi/Mlt/Rec-NM
V47 VHL m 19 PHEO Bi/Mlt-NM
H48–1 HIF2A f 29 PGL Mlt-NM
H48–4 HIF2A f 29 PGL Mlt-NM
H48–5 HIF2A f 29 PGL Mlt-NM
H48–6 HIF2A f 29 PGL Mlt-NM
H49–1 HIF2A f 18 PHEO Mlt-NM
H49–2 HIF2A f 18 PGL Mlt-NM
Abbreviations: dna, does not apply; f, female; m, male; nk, not known; PGL, paraganglioma; PHEO, pheochromocytoma (i.e. adrenal PGL); HNP, head and neck paraganglioma; pr, solitary PHEO/
PGL; mlt, multiple PGLs; bi, bilateral PHEO; m, metastatic disease; met, metastases; nm, nonmetastatic disease.
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“Core” probe sets were used to perform “gene-level” probe set
summarization, background subtraction, and quantile normaliza-
tion using the RMA option in Expression Console 1.0 (Affyme-
trix). Data analysis was performed using R packages from the
Bioconductor project (http://www.bioconductor.org), as previous-
ly described [27].
Differential expression analysis was done by significance analysis
of microarray. Class prediction analysis using prediction analysis
for microarray was done to predict the genotypes.IPA
Data were analyzed through the use of QIAGEN's IPA
(QIAGEN Redwood City, www.qiagen.com/ingenuity).
qRT-PCR for Genes of Interest
qRT-PCR was performed for nine genes of interest using Taqman
primer/probes (Life Technologies, Table S1) on a widely independent
sample set of HIF2A (n = 6), SDHB (n = 9), SDHD (n = 12), VHL
(n = 10), and normal adrenal medulla (n = 5). Patient information is
given in Table S2.
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